ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

adebrelimab

Also written as “SHR-1316”, “Adebrelimab” and “Adebrelimab Injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Pancreatic Neoplasms · Neoplasms · Breast Neoplasms, led by 2 companies.

Drug pageAdebrelimab: every studyAll 205 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 16, 201851 company-led studies, 40 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicineits history only4938 open or runningphase 3since Oct 16, 2018Apr 8, 2017Dec 2026phase 2 · NCT05482568
Hansoh Pharmaceutical Group22 open or runningphase 2since Aug 13, 2026Jul 3, 2025Mar 30, 2028phase 2 · NCT07824882

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2019Named adebrelimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, SHR-1316
  2. Jul 3, 2025First study: phase 1 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)First studyNCT07063407 · 50 planned
  3. Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07824882 · 76 planned · China

Ahead

  1. Mar 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07824882

TargetBeta

CD274 →read by rule
“An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 2 Hansoh Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07824882Carcinoma, Non-Small-Cell Lung · China2RecruitingMar 30, 202876
NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC)1Not yet recruitingApr 30, 202650

How it is read

Names in the registry

  • “SHR-1316”, 8 entries
  • “Adebrelimab”, 6 entries
  • “Adebrelimab Injection”, 4 entries
  • “adebrelimab + SHR-A2009”, 3 entries
  • “HRS-717 + HRS-4642+SHR-1316;”, 3 entries

Codes read as this program: SHR1316.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.